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INTRODUCTION 
Netilmicin is a semisynthetic aminoglycoside antibiotic recently 
marketed in the United States by Schering-Plough Corporation as 
Netromycin® . The mechanism and spectrum of antibacterial action of 
1 2 
netilmicin are similar to those of other aminoglycosides. ' 
Pulmonary infections with Pseudomonas aeruginosa are a common 
3 
complication in patients with cystic fibrosis (CF). Aminoglycosides 
currently occupy a central role in the management of these infections, 
often in combination with an extended spectrum penicillin derivative. 
4 
Thadepalli et al have demonstrated the synergism of netilmicin in 
combination with carbenicillin, ticarcillin and piperacillin to 
inhibit a number of Pseudomonas aeruginosa strains. Netilmicin may 
therefore play a role in the treatment of these infections. 
Unfortunately netilmicin, similar to all other aminoglycosides, 
1 2 
has a low therapeutic index. ' Although the optimal serum concentra-
tions have not yet been established, it is generally agreed that the 
desirable peak and trough concentrations are 6 to 10, and 0.5 to 2.0 
mcg/ml, respectively.^'^ The adequacy of a specific serum concentra-
tion for a particular patient must take into account the site and 
severity of the infection and the status of the patient's host defense 
mechanisms. 
A wide interpatient variation in aminoglycoside dosage require-
ment has been demonstrated and generalized dosage recommendations are 
often inadequate.^ As aminoglycosides have significant serum 
concentration-related toxicity, there is considerable interest in 
2 
developing alternate dosing methods and in describing the pharmaco-
kinetics of these drugs in disease states which alter kinetic para-
meters . 
The pharmacokinetic parameters of aminoglycoside antibiotics in 
children, with CF often differ from those seen in children without 
8—13 
CF. Increases in total body clearance (Cl_) and volume of distri-
D 
bution (Vd) have been demonstrated for the aminoglycosides genta-
• • 8,9 „ , . 10,11 , .. . 12,13 , __ , J micm, tobramycin and amikacin in the CF population. It 
follows that the kinetics of any new aminoglycoside to be used in this 
population should be studied in subjects with this disease so that 
appropriate doses and dosage regimens can be determined. 
14 
One such study has been reported by Michalsen et al. In this 
study comparing netilmicin kinetics in eight children with CF to those 
in eight children without this disease, the mean serum half-life (th) 
was shorter and the mean Cl„ was increased in CF patients. However 
D 
the differences were not statistically significant, and the authors 
concluded that the same dose of netilmicin may be used in the two 
populations. This conclusion is in contrast to the increased dosage 
requirement documented for other aminoglycosides in the CF population. 
Sawchuk and Zaske^ have developed a method of using serum 
concentration versus time data from a single dose to determine the 
individual patient's dosage regimen that will produce predetermined 
desirable peak and trough aminoglycoside concentrations. This method 
has been used to estimate the appropriate dosage regimens for genta-
micin^ ''''^  ^ and netilmicin^ in the non-CF population, and tobra-
mycin^ in patients with CF, and may have utility in the dosing of 
netilmicin in the CF population as well. 
3 
The objectives of this study were to further extend the limited 
information available on the elimination pharmacokinetics of netil-
micin in patients with cystic fibrosis and to determine the utility of 
the Sawchuk-Zaske (S-Z) method of dosage adjustment for netilmicin in 
this population. 
MATERIALS AND METHODS 
Study Design 
This was a descriptive pharmacokinetic study. In addition, a 
clinical comparison between serum netilmicin concentrations predicted 
by the Sawchuk-Zaske dosing method and actual measured values was 
performed. 
Patient Selection 
After approval of the proposal by the Institutional Review Board, 
ten CF patients admitted to the University of Utah Hospital Pediatric 
Service were selected for the study. All patients required parenteral 
antibiotic therapy for acute exacerbation of their disease. Written 
informed consent to participate in the study was obtained from all 
patients over 18 years of age, and from the parents of all subjects 
less than 18 years of age. (Appendix 1) Further, informed assent was 
obtained from all subjects between the ages of 12 and 18 years. 
Prospective participants were excluded from the study if the 
causative organism(s) was insensitive to netilmicin, or if the patient 
had received an aminoglycoside antibiotic in the two-week period 
preceding the study. Patients were also excluded if they had signifi-
cant renal impairment as manifested by a serum creatinine greater than 
1.2 mg/dl, significant hepatic dysfunction as manifested by a total 
bilirubin greater than 1.0 mg/dl or SGPT greater than 30 IU/1, 
4 
hypersensitivity to aminoglycosides or if they were pregnant or 
lactating. Patients whose condition make it highly unlikely that the 
course of therapy or follow-up would be completed were not accepted. 
Patient characteristics are listed in Table 1. Six patients were 
males and four were females. The mean age was 16 years with a range 
of 5 to 29 years. Mean body weight was 33 kg, ranging from 12 to 57 
kg. 
Netilmicin Therapy and Sample Collection 
Except for the aminoglycoside therapy and blood sampling, 
patients were treated according to standard procedures. This included 
the collection of a sputum specimen for Gram stain, culture and 
sensitivity testing prior to initiating antibiotic therapy. Results 
of this testing were monitored and netilmicin was discontinued in any 
patient with an insensitive organism. 
Following admission to the study separate intravenous catheters 
with attached heparin locks were inserted for blood sampling. All 
patients were started on netilmicin at the manufacturer's recommended 
dose of 2 mg/kg/dose infused over 30 minutes every eight hours. 
Concomitant antibiotic therapy was instituted with an extended spec-
trum penicillin in nine patients and chloramphenicol in the tenth. 
After a single dose of netilmicin was infused, blood samples were 
obtained at approximately 0.5, 3.0 and 7.0 hours post-infusion. The 
exact times of the infusion and collection of blood samples were 
recorded. The initial samples were analyzed for netilmicin content 
within 12 to 24 hours of collection. The resultant values were used 
to adjust the dose and/or interval to produce peak concentrations 
(Cp-max) of approximately 8.0 mcg/ml and trough concentrations 
5 
(Cp-min) of approximately 1.5 mcg/ml using the S-Z program for amino-
glycosides . 
At least 24 hours after changing to the new dose/regimen, blood 
samples were obtained pre-dose and approximately 0.5 hours post-
infusion to assure that appropriate serum concentrations were obtained 
and for comparison to predicted values. If these measured levels were 
determined to be inadequate, the dose and/or dosage regimen was 
further adjusted until the desired concentrations were obtained. 
After the last dose of netilmicin was administered (at completion 
of the course of therapy) blood samples were obtained at 0, 10, 20, 
30, 40 and 60 minutes and 2, 6, 10, and 12 hours after completion of 
the drug infusion. The exact times of infusion and blood sampling 
were recorded. Within 30 minutes after collection of samples, blood 
was centrifuged to harvest serum, which was frozen at -40°C until time 
of assay. 
Netilmicin Assay 
Serum concentrations of netilmicin were determined at the 
Clinical Toxicology Laboratory of the University of Utah Hospital, 
using a fluorescence polarization immunoassay (TDX® , Abbott, North 
Chicago, IL). The lower limit of sensitivity of the assay was 0.4 
mcg/ml. Intra-run and inter-run coefficients of variation were four 
and six percent, respectively. All samples were measured in duplicate 
and reported as the mean. 
Sawchuk-Zaske Dosing Program 
Sawchuk and Zaske have developed an aminoglycoside dosing program 
for a hand-held calculator (TI-59, Texas Instruments, Inc., Dallas, 
TX).^ The program assumes a one-compartment model and linear pharma-
cokinetics. A description of the program follows. 
Aminoglycoside serum concentration versus time data from three 
serum samples, obtained preferably after the first dose, were entered 
into the calculator. The data were fitted using least-squares regres-
sion analysis. The drug's elimination rate constant (Kel) and the 
serum concentration on the regression line at zero time post infusion 
(Cp-max) were estimated from the line of best fit. The t% was calcu-
lated by division of In 2 (0.693) by Kel. 
The program next determined the patient's Vd according to the 
relationship: 
Vd = Ko . 1-e 
Kel _ -Kel t' Cp-max - Cp-mm e 
where Ko is the infusion rate, t' is the infusion period and Cp-min is 
the pre-dose concentration. The method of calculation for Vd ac-
counted for the fraction of drug eliminated during the infusion 
period. 
A dosing interval (T) was then calculated following input by the 
user of the desired peak level (Cp-max-d), trough level (Cp-min-d) and 
t' according to the relationship: 
T = -1 . Cp-min-d + , 
Kel Cp-max-d 
7 
In this protocol, the Cp-max-d and Cp-min-d were defined as 8.0 and 
1.5 mcg/ml, respectively. The calculated T value was rounded off to a 
clinically practical time. 
The Ko required to produce the desired serum concentrations was 
calculated by the program from the equation: 
l - e _ K e l T 
Ko = Vd Kel Cp-max-d . iKeFT' 
1-e 
Using this information, the program next calculated dose in mg (D) 
from: 
D = Ko * t' 
This calculated dose is rounded off to a practical increment. 
The calculated dose and interval, rounded off to clinically 
practical values, were entered into the program for calculation of the 
predicted steady state peak (Cp-max-p) and trough (Cp-min-p) by the 
following equations: 
„ -Kel t\ Cp-max-p = Ko (1-e ) 
Kel Vd (l-e"Kel T-l) 
and 
„ , -Kel t' Cp-mm-p = Ko (e -1) 
Kel Vd (e"Kel T-l) 
If the user determines that these values are unacceptable, the program 
allows multiple combinations of dose and interval to be entered until 
an acceptable dosage regimen is determined. 
8 
Following calculations, the new dosage regimen was instituted. 
Serum levels were obtained at steady state and compared to predicted 
values. Blood collections were performed prior to a dose (Cp-min) and 
at approximately 30 minutes after the infusion (Cp-max). All exact 
times were recorded. 
Because the Cp-max-p determined by the program is the intercept 
of the best-fitted line (t=0), and inasmuch as the blood samples were 
obtained at approximately 30 minutes after the end of infusion (t = 
0.5 hours), the predicted values were further adjusted as follows. 
The natural logarithm of the Cp-max-p and Cp-min-p concentrations were 
entered into the linear regression program of the programmable calcu-
lator along with the corresponding times. With this information, the 
program calculated the concentration (Y axis value) for any time (X 
axis value) entered. The patient's actual time of blood sampling was 
entered, and the natural logarithm of the adjusted predicted value was 
obtained. 
This adjusted Cp-max-p and the Cp-min-p were compared with the 
measured netilmicin concentrations. A clinically significant dif-
ference in predicted and measured concentrations was arbitrarily 
defined as 1.0 mcg/ml. 
Statistical Analysis 
The Wilcoxon Signed Rank test was used to determine whether the 
differences between measured and predicted netilmicin concentrations 
were statistically significant. 
Further, observed serum concentrations were compared with pre-
dicted values using the statistical analysis recommended by Sheiner 
19 
and Beal. This method involves the calculation of the mean 
prediction error (me) and the root of the mean squared prediction 
error (rmse). The me is a measure of bias and estimates the magnitude 
of the systematic component of error. The rmse is a measure of 
precision. 
Pharmacokinetic Analysis 
Data from each subject were treated independently to determine 
the individual pharmacokinetic parameters. The calculated pharmaco-
kinetic parameters were later grouped to generate mean ± standard 
error of the mean (SEM) values. 
Semilogarithmic plots of serum netilmicin concentration versus 
time were made for each patient. The data were visually inspected to 
determine the end of the distribution phase and the beginning of the 
elimination phase. The beta line, with Y-intercept B and slope beta, 
was determined by best fitting a line through the data points of the 
elimination phase. The alpha line, with Y-intercept A and slope 
alpha, was determined by best fitting a line through the data points 
20 
in the distribution phase after applying the method of residuals. 
The best fit lines were determined using the curve-fitting program for 
a hand-held calculator (TI-55-II), which uses a least squares regres-
sion method. The slope of the alpha line is the disposition rate 
constant (a) and the slope of the beta line is the disposition rate 
constant (3). The a and g half-lives were determined by dividing In 2 
(0.693) by a and 3, respectively. 
The apparent volume of distribution at steady state ( v d g g ) a n d 
the total body clearance (CI ) were calculated by noncompartmental 
B 
20 
analysis, corrected for infusion times. This method uses the 
following relationships: 
10 





CI = Dose 
AUC 
where AUMC and AUC are the area under the first moment of the serum 
concentration versus time curve, and the area under the serum concen-
tration versus time curve, respectively, calculated by the trapezoidal 
rule, and t' is the infusion time. 
RESULTS 
Sawchuk-Zaske Dosing Program 
Predicted and measured values for Cp-max and Cp-min for each 
patient are presented in Tables 2 and 3. The graphic presentations of 
the relationship between measured and predicted concentrations are 
displayed in Figures 1 and 2. 
Of the 10 patients, 7 had peak netilmicin levels different enough 
from those predicted by the S-Z program to be considered clinically 
significant by our criteria. The me and rmse were + 0.9 mcg/ml and 
2.0 mcg/ml, respectively. As a result of the measured Cp-max, two 
patients needed subsequent dosage reductions, and two required in-
creased doses. Differences between measured and predicted peak 
concentrations were not statistically significant (p > .05). Using 
the same criteria to evaluate trough concentrations, we found that the 
differences between measured and predicted values were not clinically 
significant. All measured trough concentrations were higher than 
predicted values, with a me and rmse of + 0.4 mcg/ml and 0.5 mcg/ml, 
respectively. No dosage adjustment was required on the basis of 
trough concentrations. Differences between measured and predicted 
values were statistically significant in this case (p < .05). 
Pharmacokinetic Parameters 
Semilogarithmic plots of serum netilmicin concentration versus 
time for each patient are displayed in Figures 3 through 12. Calcu-
lated pharmacokinetic parameters for each subject and mean ± SEM are 
presented in Table 4. Mean (± SEM) values for the disposition rate 
constants a and 3 and the a and 3 half-lives were 4.63 (± 0.59) hr 1, 
0.381 (± 0.19) hr"1, 0.18 (± 0.03) hr, and 1.87 (±0.10) hr, respec-
tively. The mean (± SEM) Vd g g and CL^ calculated by noncompartmental 
analysis were 0.38 (± 0.01) 1/kg and 2.62 (±0.18) ml/min/kg, 
respectively. 
During data analysis, a difference between each patient's netil-
micin calculated by the S-Z method (when initiating therapy) and 
the th calculated using serum concentration-time data from the elimi-
nation phase of the last netilmicin dose was observed. Half-life 
values and differences are presented in Table 5. Using the Wilcoxon 
Signed Rank test, these differences were statistically significant 
(p < .05). The mean difference was 0.44 hr. 
DISCUSSION 
Sawchuk-Zaske Dosing Program 
Sawchuk, Zaske and their associates have published numerous 
reports that support the use of their method of individualizing the 
dose of gentamicin in the non-CF population.^'^ ^ Rotschafer et al^ 
recently reported the successful use of this method to derive dosage 
regimens for netilmicin in 27 non-CF patients, but they used a clini-
cally impractical minimum of six serum samples to estimate the pharma-
cokinetic parameters. These studies do not report the proportion of 
patients requiring dosage adjustment following the initial estimate or 
the total number of dosage adjustments made per patient. Kelly et 
al1^ reported the successful use of this method to estimate tobramycin 
dosage in 12 patients with CF. In Kelly's study the investigators 
report a trend for the peak values of tobramycin to be higher than 
predicted, but no concentrations above 12 mcg/ml were reported. 
Our results with this dosing system were favorable although both 
the measured peak and trough serum concentrations tended to be higher 
than predicted. Based on measured peak concentrations, 4 of 10 
patients required one further dosage adjustment. No adjustments were 
required on the basis of the trough values. Predicted trough values 
were more precise than predicted peak values as demonstrated by the 
calculated rmse of 0.5 mcg/ml for the Cp-min-p versus 2.0 mcg/ml for 
the Cp-max-p. 
The S-Z method did allow us to arrive efficiently at reasonable 
dosage regimens in this population. However, this method of predict-
ing dosage requirements was not uniformly accurate. Therefore, we 
would recommend serum concentration verification at steady state 
following any adjustment in dosage. Thereafter, periodic determi-
nations may also be necessary to assure that therapeutic antibiotic 
concentrations have been maintained and to prevent toxicity. 
13 
In our study, the t% estimated by the S-Z method, on which dosage 
recommendations were based, was not representative of the th calcu-
lated for each patient at the end of therapy. This finding may result 
from a combination of the collection of the first blood sample during 
the distributive phase and changes in CI during the course of 
therapy. Our study was not designed to address this question, but 
this observation lends support to our recommendation of monitoring 
peak and trough serum concentrations periodically throughout the 
course of therapy. 
Pharmacokinetic Analysis 
Altered pharmacokinetic parameters in patients with CF have been 
g 
reported by several investigators. Kearns et al reported an increase 
in gentamicin Vd, CI..,, and required dose in 17 patients with CF when 
compared to controls. Mean values for Vd and CLg in CF patients were 
0.34 1/kg and 2.51 ml/min/kg compared to control values of 0.24 1/kg 
and 1.36 ml/min/kg. The mean dose required to produce a Cp-max of 7.5 
mcg/ml in CF and non-CF patients was 9.9 mg/kg/day and 6.8 mg/kg/day, 
respectively. Kelly et al1^ studied 12 patients receiving tobramycin 
and reported an increased mean Vd and Cl^ of 0.37 1/kg and 3.68 
ml/min/kg, respectively. In agreement with these findings, Fraser et 
al11 reported three CF patients with an increased mean Vd of 0.37 
9 
1/kg. In a recent report, Bauer et al compared gentamicin and 
tobramycin pharmacokinetics in patients with CF. They found no 
significant differences between the pharmacokinetic parameters of the 
two drugs. Mean Vd and CI were both increased with values for 
tobramycin of 0.33 1/kg and 2.98 ml/min/kg and for gentamicin of 0.35 
1/kg and 2.70 ml/kg/min, respectively. Dosage requirements were 
14 
increased, with mean tobramycin doses of 11 mg/kg/day and gentamicin 
doses of 10 mg/kg/day. All of these investigators determined their 
reported kinetic parameters using the one-compartment analysis of 
Sawchuk and Zaske. On re-analysis of data originally collected by 
12 13 Vogelstein et al, Anderson et al demonstrated a significantly 
greater amikacin CI in 11 patients with CF when compared to 9 
patients without CF. Mean CI,, values for the CF and non-CF groups 
2 2 
were 105 ml/min/1.73m and 88 ml/min/1.73m , respectively. No signifi-
cant difference in Vd was noted. Vogelstein et al analyzed their data 
according to a multicompartmental model. 
21 
In contrast, MacDonald et al reported no statistically signifi-
cant differences in gentamicin Vd or CI between the ten non-acutely 
15 
ill patients with CF he studied and values reported in the literature 
for non-CF patients. Data analysis was performed using two-
compartment modeling. He concluded that larger doses were not neces-
sary in the CF population. 
The mean netilmicin Vd and Cl^ reported in patients without CF 
9 22 23 
are 0.25 1/kg and 1.42 ml/min/kg, respectively. ' ' Our data are 
thus consistent with the increased and Cl^ previously reported 
for aminoglycosides in patients with CF and are in contrast to the 
results of Michalsen and Bergan. As the Cl^ of a drug is inversely 
D 
related to the serum concentration at a given dose, these data suggest 
that an increased dose is required in patients with CF. 
It may be concluded from these results that the pharmacokinetic 
disposition of netilmicin in patients with CF differs from that in 
patients without this disease. The data demonstrate considerable 
15 
variations in the disposition of this drug between patients, and 
therefore the optimal dose and regimen for each patient must be 
determined individually. 
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Figure 11: Netilmicin serum concentration 
versus time. Patient 9. 

TABLES 
Table 1. Patient Characteristics 
Patient Sex Age (yr) Weight (kg) S. Creat. (mg%) 
1 F 29 33.4 0.8 
2 M 24 24.0 0.4 
3 M 23 43.2 0.8 
4 M 13 34.1 0.6 
5 F 17 48.5 0.7 
6 M 12 23.5 0.5 
7 M 14 29.0 0.8 
8 F 5 12.8 0.6 
9 M 18 57.0 0.8 
10 F 6 15.2 0.5 
Mean 16 33.1 0.65 
31 
Table 2. Comparison of netilmicin peak concentrations 
measured with those predicted 
Measured Predicted** 
Patient Cp-max (meg/ml) Cp-max (mcg/ml) Difference 
1 6.0 5.9 +0.1 
2 7.6 5.8 +1.8 
3 10.0 7.4 +2.6 
4 6.0 5.2 +0.8 
5 5.7 7.5 -1.8 
6 9.5 6.0 +3.5 
7 8.5 5.9 +2.6 
8 8.1 6.2 +1.9 
9 4.8 6.6 -1.8 
10 4.9 5.6 -0.7 
Mean +0.9 
Measured Cp-max - Adjusted predicted Cp-max 
** 
Predicted values adjusted to time of actual serum sampling 
32 
Table 3. Comparison of netilmicin trough concentrations 
measured with those predicted 
Measured Predicted 
Patient Cp-min (meg/ml) Cp-min (mcg/ml) Difference 
1 1.4 0.8 +0.6 
2 0.7 0.5 +0.2 
3 1.7 1.0 +0.7 
4 0.5 0.3 +0.2 
5 1.2 0.7 +0.5 
6 0.8 0.6 +0.2 
7 1.1 0.6 +0.5 
8 0.6 0.5 +0.1 
9 1.5 0.7 +0.8 
10 0.7 0.3 +0.4 
Mean +0.4 
* 
Measured Cp-min - Predicted Cp-min 
33 
Table 4. Netilmicin pharmacokinetic parameters 
a t^a g tJsg Vdss Clg 
Patient (hr ) (hr) (hr ) (hr) L/kg ml/min/kg 
1 3.57 0.19 0.277 2.50 0.35 1.83 
2 4.53 0.15 0.465 1.49 0.41 3.16 
3 3.29 0.21 0.296 2.34 0.32 1.67 
4 3.58 0.19 0.392 1.77 0.34 2.94 
5 6.98 0.10 0.375 1.85 0.34 2.72 
6 6.47 0.11 0.438 1.58 0.44 3.45 
7 3.67 0.19 0.341 2.03 0.38 2.21 
8 1.79 0.39 0.399 1.74 0.45 2.66 
9 4.67 0.15 0.381 1.82 0.41 2.70 
10 7.77 0.09 0.442 1.57 0.37 2.83 
Mean 4.63 0.18 0.381 1.87 0.38 2.62 
SEM 0.59 0.03 0.019 0.10 0.014 0.18 
Table 5. Comparison of t% determined at the 
beginning and end of therapy 
Beginning (hr) Ending th (hr) Difference 
1.69 2.50 + 0.81 
1.31 1.49 + 0.18 
1.74 2.34 + 0.60 
1.11 1.77 + 0.66 
1.46 1.85 + 0.39 
1.46 1.58 + 0.12 
1.45 2.03 + 0.58 
1.41 1.74 + 0.33 
1.56 1.82 + 0.26 
1.11 1.57 + 0.46 
Mean 1.43 1.87 + 0.44 
* 
Calculated by Sawchuk-Zaske method 
Calculated using data points from elimination phase of last dose 
. 
APPENDIX 
PHARMACOKINETICS OF NETILMICIN IN CYSTIC FIBROSIS 
Consent Form 
Date 
One of the aspects of the treatment of your/your child's lung 
infection is aminoglycoside antibiotic therapy. To ensure the anti-
biotic therapy is effective and to. minimize potential side effects it 
is important to use the correct dose and follow the blood levels of 
these drugs closely. The purpose of this study which you are being 
invited to participate is to evaluate the amount of netilmicin (a new 
aminoglycoside antibiotic) necessary to maintain proper blood levels 
in patients with cystic fibrosis. You/Your child will be given netil-
micin in the usual recommended dose. The study requires having blood 
drawn on three separate occasions. After the third dose of the drug, 
three blood samples will be drawn. Your antibiotic dose will be 
adjusted, if necessary, based on these results. Two blood samples 
will be drawn to check the dose if a change was made. In the 12 hours 
following the last dose, 11 blood samples will be collected. Total 
blood collected for this study will be about one and one-half ounces 
(lh tablespoonfuls). Four urine collections will also be done during 
this last 24 hours. 
Since you will receive a similar antibiotic, e.g., tobramycin, as 
part of your usual treatment if you decide not to participate in this 
study, the only added risk involved in the study is the taking of 
blood, as mentioned above. Risks of this procedure are discomfort, 
inflammation and bruising. The potential benefits of participation in 
this study are closer evaluation of disease status and hospital course 
and possibly more effective and safer treatment. 
If you have any questions during the study, you may contact Dr. 
John Bosso (581-7545) or Dr. John Herbst (581-8227). In the event you 
sustain physical injury resulting from the research project in which 
you are participating, the University of Utah will provide you, 
without charge, emergency and temporary medical treatment not other-
wise covered by insurance. Furthermore, if your injuries are caused 
by negligent acts or omissions of University employees acting in the 
course and scope of their employment, the University may be liable, 
subject to limitations prescribed by law, for additional medical costs 
and other damages you sustain. If you believe that you have suffered 
a physical injury as a result of participating in this research 
program, please contact the Office of Research Administration, tele-
phone number 581-6903. 
Participation in this study is voluntary. I acknowledge that I 
have had a fair opportunity to ask questions about the above proce-
dures. I understand that I am free to withdraw my consent for my 
child and to discontinue his or her participation in the project at 
any time without prejudice. I agree that data from these experiments 
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may be used for medical and scientific purpose, including publica-
tions, with the understanding that my identity will not be revealed 
unless I expressly consent thereto. 
Patient Name: Signature: 
Witness: Parent or Guardian Signature: 
Responsible Investigator's Signature: 
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ics, adverse reactions and clinical efficacy. Pharmacotherapy. 
1983; 3:305-15. 
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in patients with cystic fibrosis. J Pediatr. 1981; 98:173-9. 
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12-20. 
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12. Vogelstein B, Kowarski AA, Lietman PS. The pharmacokinetics of 
amikacin in children. J Pediatr. 1977; 91:333-9. 
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